EAPSI: Establishing cellular biomarker levels and biological function in lung Cancer

EAPSI：建立肺癌细胞生物标志物水平和生物学功能

• 批准号: 1414956
• 负责人: Casey Burton
• 金额: $ 0.51万
• 依托单位: Burton Casey
• 依托单位国家: 美国
• 项目类别: Fellowship Award
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-06-01 至 2015-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1414956&HistoricalAwards=false
• 关键词: EAPSI; Establishing; cellular; biomarker; levels

Pteridines are an emerging class of metabolic biomarkers that show promise as noninvasive indicators of malignancies such as lung cancer. Recent advancements in pteridine detection have elucidated the biological function of pteridines and establish cellular levels in cancer cell lines. Using a combination of powerful detection platforms, this study aims to establish cellular pteridines levels in multiple human cell lines in order to propose novel pteridine mechanisms in lung cancer and to generate corresponding pteridine profiles that can be used for clinical screening purposes. These pteridine profiles will enable clinical practitioners to advance pteridine validation studies and facilitate the rapid translation of pteridine diagnostics into clinical practice while mechanism elucidation will enable new anti-cancer technologies. This research will be conducted in collaboration with Dr. Huwei Liu, a leading expert in bioseparations, at Peking University which affords unique access to world-class cell culture facilities.This study will utilize a novel capillary electrophoresis - laser-induced fluorescence (CE-LIF) pteridine detection technique to monitor 15 clinically important pteridines in an established human lung cancer cell line and normal human embryonic kidney cells which will be used as a control. Pteridine functionality will be determined through activation/inhibition of metabolic pathways using well-established methods. Cellular pteridine levels will also be characterized to predicate the elevated levels clinically reported in urine matrices. Simultaneous analysis by liquid chromatography - tandem mass spectrometry (LC-MS/MS) will permit identification of new clinically useful pteridine derivatives. Pteridine profiles including the 15 clinically important pteridines and any newly identified pteridine derivatives will be produced for lung cancer and control embryonic kidney cell lines as a new diagnostic tool. This NSF EAPSI award is funded in collaboration with the Chinese Ministry of Science and Technology.

蝶啶是一类新兴的代谢生物标志物，有望作为肺癌等恶性肿瘤的非侵入性指标。蝶啶检测的最新进展已经阐明了蝶啶的生物学功能并建立了癌细胞系中的细胞水平。使用强大的检测平台的组合，本研究的目的是建立细胞的蝶啶水平在多种人类细胞系，以提出新的蝶啶机制在肺癌，并产生相应的蝶啶档案，可用于临床筛选的目的。这些蝶啶谱将使临床医生能够推进蝶啶验证研究，并促进蝶啶诊断快速转化为临床实践，而机制阐明将使新的抗癌技术成为可能。这项研究将与生物分离领域的领先专家Huwei Liu博士合作，本研究将利用新型毛细管电泳-激光诱导荧光（CE-LIF）技术，蝶啶检测技术，用于监测已建立的人肺癌细胞系和正常人胚胎肾细胞中的15种临床重要的蝶啶，将被用作对照。蝶啶的功能性将通过使用成熟的方法激活/抑制代谢途径来确定。还将表征细胞蝶啶水平，以预测临床上报告的尿液基质中水平升高。液相色谱-串联质谱（LC-MS/MS）的同时分析将允许鉴定新的临床有用的蝶啶衍生物。蝶啶概况，包括15个临床上重要的蝶啶和任何新鉴定的蝶啶衍生物将产生肺癌和对照胚胎肾细胞系作为一种新的诊断工具。NSF EAPSI奖是与中国科技部合作资助的。